If you are considering a GLP-1 medication like semaglutide (Wegovy) or tirzepatide (Zepbound) for weight loss, one of the first questions you probably have is whether your insurance will cover it. The short answer: it depends on your plan, your BMI, and sometimes which medication your doctor prescribes. The longer answer is what this post walks through.
Why Insurance Coverage for Weight Loss Medications Is Complicated
GLP-1 medications were originally approved for type 2 diabetes. Ozempic (semaglutide 0.5mg, 1mg, 2mg) and Mounjaro (tirzepatide) carry diabetes indications with relatively broad insurance coverage. But when the same drugs are prescribed for weight loss under the brand names Wegovy and Zepbound, insurance gets more complicated.
The difference comes down to how your policy classifies weight management. Some plans treat obesity as a chronic disease and cover FDA-approved weight loss medications. Others have explicit exclusions for weight loss drugs, or they require you to try and fail other approaches first, what insurance calls step therapy.
What Most Insurance Plans Require Before They Will Approve Coverage
Even when a plan does cover GLP-1 medications for weight loss, you will almost always need prior authorization. Here is what that process typically looks like:
A documented BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, prediabetes, high cholesterol, or sleep apnea
Proof that you have attempted lifestyle modifications such as diet and exercise, sometimes for six months or more, documented in your medical records
No contraindications, meaning no personal or family history of medullary thyroid carcinoma or MEN2 syndrome
Your prescriber must submit a prior authorization form with supporting documentation from your medical records
Commercial Insurance vs. Medicare vs. Medicaid
Coverage varies significantly depending on the type of insurance you have:
Commercial/employer plans: The most variable category. Some large employers cover GLP-1 medications, but many smaller plans exclude weight loss drugs entirely. If your employer offers a formulary lookup tool, search for Wegovy or Zepbound by name to see if they are listed.
Medicare Part D: As of early 2026, Medicare Part D plans can cover GLP-1 medications prescribed for obesity when deemed medically necessary. This is a recent change. Previously, Medicare had a blanket exclusion on weight loss drugs. Check your specific Part D formulary for updated coverage details.
Medicaid: Coverage is state by state. Texas Medicaid generally does not cover weight loss medications, but exceptions exist for patients with type 2 diabetes.
ACA marketplace plans: These plans vary. Some cover GLP-1 medications under preventive services if you meet BMI thresholds, while others exclude them.
What If Your Insurance Denies Coverage?
A denial is not the end of the road. At FloMD, we handle prior authorization submissions and appeals as part of your care. If your initial request is denied, we can:
Submit an appeal with additional medical documentation supporting medical necessity
Request a peer-to-peer review where I speak directly with the insurance company's medical director
Explore manufacturer savings programs that can bring the cost down substantially for eligible patients, both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer these
Discuss alternative medications that your plan may cover more readily, such as oral options or lower-dose formulations
Manufacturer Savings Programs
Even without insurance coverage, both Novo Nordisk and Eli Lilly offer patient assistance programs:
Wegovy Savings Offer: Eligible commercially insured patients may pay as little as $0 per month for the first 6 months, then $148 per month after. Terms change, so check wegovy.com for current details.
Zepbound Savings Offer: Eli Lilly offers a savings card that can reduce out-of-pocket costs for commercially insured patients. Check zepbound.lilly.com for current pricing.
Patient assistance for uninsured patients: Both manufacturers offer programs for patients who meet income eligibility requirements. These programs can provide medication at no cost.
The Real Monthly Cost Without Insurance
For patients paying entirely out of pocket, here is a realistic picture of current list prices:
Wegovy: Around $1,350 per month at list price before any discounts or savings programs
Zepbound: Around $1,060 per month at list price before discounts
Compound versions: We do prescribe compounded GLP-1 medications at FloMD and these start at $169.
These prices are the starting point. With manufacturer discounts, many patients pay significantly less.
How FloMD Helps You Navigate This
We do not just write a prescription and hope your insurance covers it. At FloMD Primary Care, our process includes:
A thorough medical evaluation to confirm GLP-1 therapy is appropriate for you
Benefits verification before you start, so you know exactly what your plan covers and what your out-of-pocket cost will be
Prior authorization submission handled by our team, with all supporting documentation included
Appeals and peer-to-peer reviews if your initial request is denied
Ongoing monitoring and dose adjustments as part of your regular follow-up visits
If you have been thinking about GLP-1 therapy but are not sure about the insurance side, schedule a consultation. We will review your coverage, walk you through your options, and help you make an informed decision before you spend a dollar out of pocket.
